Sun gets FDA ok for ketorolac ophthalmic solution
This article was originally published in Scrip
A subsidiary of Sun Pharmaceutical Industries has received US FDA approval for an ANDA for ketorolac tromethamine ophthalmic solution, 0.5%, a generic version of Allergan's Acular. Ketorolac tromethamine ophthalmic solution is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis and also in the treatment of post-operative inflammation in patients who have undergone cataract surgery. The product generated annual sales of about $40 million in the US.
You may also be interested in...
Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.